| Trial ID: | L4906 |
| Source ID: | NCT01843855
|
| Associated Drug: |
Exendin 9,39
|
| Title: |
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Exendin 9,39|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB), The total disposition index equals the product of insulin secretion and insulin sensitivity., baseline, 4 weeks post-operative intervention |
|
| Sponsor/Collaborators: |
Sponsor: Adrian Vella | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-06
|
| Completion Date: |
2013-09
|
| Results First Posted: |
|
| Last Update Posted: |
2013-12-04
|
| Locations: |
Mayo Clinic, Rochester, Minnesota, 55905-0001, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01843855
|
